Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00876421
NCT00876421
Completed
Phase 2

A Randomised, Multi-Centre, Double-Blind, Placebo and Active-Controlled, 5-Way Parallel Group Study to Investigate the Efficacy, Safety and Tolerability of ONO-8539 in Patients With Overactive Bladder

Ono Pharmaceutical Co. Ltd0 sites435 target enrollmentApril 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsOveractive Bladder
InterventionsPlaceboTolterodineONO-8539
DrugsPlaceboTolterodineONO-8539

Overview

Phase
Phase 2
Intervention
Placebo
Conditions
Overactive Bladder
Sponsor
Ono Pharmaceutical Co. Ltd
Enrollment
435
Primary Endpoint
Overactive bladder symptoms
Status
Completed
Last Updated
13 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSimilar Trials

Overview

Brief Summary

The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.

Registry
clinicaltrials.gov
Start Date
April 2009
End Date
April 2010
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Patients with medical history of Overactive Bladder symptoms for \> 6 months

Exclusion Criteria

  • •Patients who have a history or presence of other significant diseases, which in the opinion of the investigator, might compromise the patient's safety or the evaluation of the study results

Arms & Interventions

P

Intervention: Placebo

A

Intervention: Tolterodine

E1

Intervention: ONO-8539

E2

Intervention: ONO-8539

E3

Intervention: ONO-8539

Outcomes

Primary Outcomes

Overactive bladder symptoms

Time Frame: 12 weeks

Secondary Outcomes

  • Overactive bladder symptoms (QOL)(12 weeks)

Similar Trials

Completed
Phase 2
Study of ONO-8577 in Patients With Overactive BladderOveractive Bladder
NCT03106623Ono Pharmaceutical Co. Ltd207
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult SubjectsHealthy Adult Subjects
NCT01405651Ono Pharma USA Inc24
Completed
Phase 2
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung CancerAdvanced Non-small Cell Lung Cancer (NSCLC)
NCT02175017Ono Pharmaceutical Co. Ltd104
Completed
Phase 2
Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive DisorderMajor Depressive Disorder
NCT00514865Ono Pharma USA Inc278
Completed
Phase 1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult SubjectsHealthy Adult Subjects
NCT01297582Ono Pharma USA Inc56